Centiva Capital’s AbCellera Biologics ABCL Stock Holding History

Centiva Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$503K	–	1268
2025 Q3	$503K	Buy	+100,000	New	+$441K	﹤0.01%	637

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centiva Capital's ABCL Position: Q2 2025 in Review

Centiva Capital sold out of AbCellera Biologics (ABCL) in Q2 2025, closing a stake of 46,621 shares — an estimated $104K sold.

Centiva Capital first reported a position in ABCL in Q1 2021 and held it in 3 quarters. The position peaked at $535K in Q1 2021. 128 funds tracked by Wall St. Rank hold ABCL as of Q2 2025.

Centiva Capital reported no remaining AbCellera Biologics position as of Q2 2025 after selling out during the quarter.
Centiva Capital sold 46,621 AbCellera Biologics shares in Q2 2025, an estimated $104K.
Centiva Capital first reported a position in AbCellera Biologics in Q1 2021 and held it in 3 quarters.
Centiva Capital's AbCellera Biologics position peaked at $535K in Q1 2021.
128 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.